Bulevirtide

• CAT Number: I042543
• CAS Number: 2012558-47-1
• Molecular Formula: C248H355N65O72
• Molecular Weight: 5398.86
• Purity: ≥95%

Bulevirtide (Cat No.: I042543) is a first-in-class entry inhibitor approved for the treatment of chronic hepatitis D virus (HDV) infection. It targets the sodium taurocholate co-transporting polypeptide (NTCP) receptor on hepatocytes, blocking the entry of both HDV and hepatitis B virus (HBV) into liver cells. By preventing viral entry, Bulevirtide reduces viral load and liver inflammation. It offers a novel antiviral mechanism and represents a significant advancement in managing HDV, a highly aggressive form of viral hepatitis with limited treatment options.

Reference

[1]. Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442.
[Content Brief]

[2]. Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858.
[Content Brief]

[3]. Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1(4):278-285.
[Content Brief]

[4]. Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58(5):861-7.
[Content Brief]

[5]. Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7(1):186.
[Content Brief]